Cold-EEZE Claims Chilled By Zicam Maker’s NAD Challenge
This article was originally published in The Tan Sheet
Executive Summary
NAD says ProPhase should alter claims about how much Cold-EEZE reduces the duration of colds, in a decision on a case brought by competitor Matrixx Initiatives. The advertising watchdog group calls for tweaks to a number of ProPhase’s claims.
You may also be interested in...
Boots' Symptoms Claim For Dual Defence Not A Prevention Pitch – UK Regulator
Boots UK’s display ad for its Dual Defense cold and flu symptom nasal spray was unlikely to deceive consumers to think it could prevent infection, UK Advertising Standards Authority says, which found that text in a poster ad sufficiently "conceptualized" the claim.
Zicam Creates A Monster With Reanimated Brand
Matrixx aims to make more consumers aware they can shorten the duration of a cold rather than treat the symptoms without affecting how long the cold lasts. New advertising introduces the “Cold Monster” to remind consumers to use Zicam products when they feel the first signs of a “monster of a cold.”
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.